TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23546328

Group type: EXPERIMENTAL
Intervention: Sterilized plastic fields
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disinfection with 70% alcohol and 1% iodine solutions
Number of subjects: 0
Study: 21473976

Group type: COMPARATOR
Intervention: Blacks
Number of subjects: 1331
Study: 19421678

Group type: EXPERIMENTAL
Intervention: Oral water soluble contrast agent (Group A)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional management (Group B)
Number of subjects: 41
Study: 16955991

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 138

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Imipramine with lithium addition
Number of subjects: 138

Group type: COMPARATOR
Intervention: Fluvoxamine with lithium addition
Number of subjects: 138
Study: 14767813

Group type: COMPARATOR
Intervention: Ganciclovir implant plus oral placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ganciclovir implant plus oral ganciclovir
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir
Number of subjects: 57
Study: 11722963

Group type: EXPERIMENTAL
Intervention: Lactoovovegetarian diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nonvegetarian diet
Number of subjects: 18
Study: 9396394

Group type: EXPERIMENTAL
Intervention: CADO (cyclophosphamide 300 mg/m2/d on days 1 to 5, vincristine 1.5 mg/m2/d on days 1 and 5, doxorubicin 60 mg/m2/d on day 5)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: CVP (cisplatin 40 mg/m2/d and etoposide 100 mg/m2/d on days 1 to 5)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: CADO/CVP (combined treatment)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Continuous infusion (CI) of cisplatin
Number of subjects: 183

Group type: COMPARATOR
Intervention: Bolus (BO) of cisplatin
Number of subjects: 183

Group type: COMPARATOR
Intervention: Both CI and BO
Number of subjects: 183
Study: 8193968

Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide (Buscopan)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Glucagon
Number of subjects: 66
Study: 3285536

Group type: EXPERIMENTAL
Intervention: Triple-drug therapy (low doses of cyclosporine, azathioprine, and steroids)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Double-drug therapy (higher doses of cyclosporine plus steroids)
Number of subjects: 100
Study: 30735533

Group type: EXPERIMENTAL
Intervention: Emergency unit utilization in 2014
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Emergency unit utilization in 2017
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Outpatient care utilization in 2014
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Outpatient care utilization in 2017
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Hospitalization rates in 2014
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Hospitalization rates in 2017
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Change in emergency unit utilization
Number of subjects: 619
Study: 28110270

Group type: EXPERIMENTAL
Intervention: Lancet
Number of subjects: 40

Group type: COMPARATOR
Intervention: 26-gauge needle
Number of subjects: 40
Study: 25456290

Group type: EXPERIMENTAL
Intervention: Handheld electrocautery device on 'coagulation setting'
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sharp dissection with scalpel and monopolar electrocautery forceps
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Liposuction at the time of abdominoplasty
Number of subjects: 102
Study: 23451237

Group type: EXPERIMENTAL
Intervention: Intervention group (n=277)
Number of subjects: 559

Group type: COMPARATOR
Intervention: Control group (n=282)
Number of subjects: 559
Study: 21877762

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg (DEX group, n=21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (C group, n=21)
Number of subjects: 42
Study: 19176296

Group type: EXPERIMENTAL
Intervention: Miniaturized extracorporeal circuits (MEC)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Conventional bypass
Number of subjects: 450
Study: 16501636

Group type: EXPERIMENTAL
Intervention: 10 microg/kg G-CSF for 6 days after percutaneous coronary intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 50
Study: 12802879

Group type: EXPERIMENTAL
Intervention: 20 mg cortisol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 40 mg cortisol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 10992963

Group type: EXPERIMENTAL
Intervention: Mivazerol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8797976

Group type: EXPERIMENTAL
Intervention: Whitacre spinal needle
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quincke spinal needle
Number of subjects: 100
Study: 1510446

Group type: EXPERIMENTAL
Intervention: Netilmicin 5 mg/kg once daily
Number of subjects: 144

Group type: COMPARATOR
Intervention: Netilmicin 2 mg/kg thrice daily
Number of subjects: 144
Study: 6649721

Group type: EXPERIMENTAL
Intervention: Sauna bath
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Running treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30816124

Group type: EXPERIMENTAL
Intervention: Ologen (placed over the valve's plate)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (Conventional surgery with Ahmed valve)
Number of subjects: 58
Study: 29504578

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Corticosteroid injection (CSI)
Number of subjects: 97
Study: 26385599

Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting (ADF)
Number of subjects: 121
Study: 24947080

Group type: EXPERIMENTAL
Intervention: Critical limb ischemia (CLI) patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 37
Study: 22958958

Group type: EXPERIMENTAL
Intervention: PVI with renal artery denervation
Number of subjects: 27

Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 27
Study: 20580483

Group type: EXPERIMENTAL
Intervention: ERSPC risk calculator
Number of subjects: 525

Group type: COMPARATOR
Intervention: PCPT risk calculator
Number of subjects: 525

Group type: COMPARATOR
Intervention: PSA alone
Number of subjects: 525

Group type: COMPARATOR
Intervention: PCPT model
Number of subjects: 525
Study: 18076236

Group type: EXPERIMENTAL
Intervention: Kayak ergometer protocol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Arm crank protocol
Number of subjects: 15
Study: 11730588

Group type: EXPERIMENTAL
Intervention: Neodosis software package
Number of subjects: 54

Group type: COMPARATOR
Intervention: No computer support (control)
Number of subjects: 54
Study: 9454384

Group type: EXPERIMENTAL
Intervention: Various hemostasis indexes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prothrombin index, activated partial thromboplastin index
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prothrombin's inactive forms (prethrombin‐1, decarboxylated prethrombin etc.), ecamulin index
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Velocity bend of distraction of fibrin clot, velocity bend of forming of fibrin clot, height of clot using turbidimetric method
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Half‐lysis time, lysis time, time of fibrin clot using turbidimetric method
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Velocity, Intensity, remainder of platelet aggregation induced by ADP 10 mcg/ml, 2.5 mcg/ml, 1.9 mcg/ml
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thrombin time
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Protein C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Platelet count
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Soluble fibrin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ancystron time
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: X factor
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Antithrombin‐III
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fibrin(ogen) degradation products
Number of subjects: 30
Study: 8216397

Group type: EXPERIMENTAL
Intervention: cM‐T412 50 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: cM‐T412 100 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: cM‐T412 10 mg
Number of subjects: 32
Study: 3688417

Group type: EXPERIMENTAL
Intervention: Topical lidocaine anesthesia
Number of subjects: 240

Group type: COMPARATOR
Intervention: No topical lidocaine anesthesia (Control)
Number of subjects: 240
Study: 29757876

Group type: EXPERIMENTAL
Intervention: Extended carboplatin infusion (3-hour infusion)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard carboplatin infusion (30-minute infusion)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Single-agent carboplatin
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Carboplatin with gemcitabine
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Carboplatin with paclitaxel
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Number of subjects: 146
Study: 28028918

Group type: EXPERIMENTAL
Intervention: Mailed outreach intervention promoting cholesterol testing and facilitated test ordering (without requiring an office visit)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 480
Study: 26580802

Group type: EXPERIMENTAL
Intervention: SMS Assessments + Feedback (SA+F)
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: SMS Assessments (SA)
Number of subjects: 765

Group type: COMPARATOR
Intervention: Control
Number of subjects: 765
Study: 22954201

Group type: EXPERIMENTAL
Intervention: Olmesartan/amlodipine (5/20 mg)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Olmesartan (20 mg)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Amlodipine (10 mg)
Number of subjects: 276
Study: 21680153

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 400mg once-daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800mg once-daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1200mg once-daily
Number of subjects: 51
Study: 18922236

Group type: EXPERIMENTAL
Intervention: Drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16782489

Group type: EXPERIMENTAL
Intervention: Enhanced feedback of practice requesting rates for nine laboratory tests
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Brief educational reminder messages added to test result reports for nine laboratory tests
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Both enhanced feedback and reminder messages
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 370
Study: 12670616

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 172
Study: 10887926

Group type: EXPERIMENTAL
Intervention: Phenylephrine 10%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Phenylephrine 10% + Flurbiprofen
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Phenylephrine 2.5%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Phenylephrine 2.5% + Flurbiprofen
Number of subjects: 100
Study: 8692536

Group type: EXPERIMENTAL
Intervention: Cisplatin plus D-Trp-6-LHRH (decapeptyl)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 34
Study: 1306775

Group type: EXPERIMENTAL
Intervention: Many punctures of low quantity sclerosant
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: One puncture of large quantity sclerosant
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: One puncture of large quantity sclerosant with transendoscopic balloon
Number of subjects: 60
Study: 30064408

Group type: EXPERIMENTAL
Intervention: Physiotherapy plus conventional treatment
Number of subjects: 134

Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 134
Study: 26723196

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg daily until delivery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24228683

Group type: EXPERIMENTAL
Intervention: Comprehensive WASH improvements in water-scarce schools
Number of subjects: 185

Group type: COMPARATOR
Intervention: School hygiene promotion and water treatment interventions and school sanitation improvements in schools with greater water availability
Number of subjects: 185
Study: 23649064

Group type: EXPERIMENTAL
Intervention: Gates‐Glidden drills with apical stop prepared with #25 Flexofile files
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gates‐Glidden drills with apical stop prepared with #30 Flexofile files
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gates‐Glidden drills with apical stop prepared with #35 Flexofile files
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ProTaper rotary instruments with apical stop prepared with F1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ProTaper rotary instruments with apical stop prepared with F2
Number of subjects: 50

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 50
Study: 21190603

Group type: EXPERIMENTAL
Intervention: Total saponins of Panax notoginseng (PNS) extract Xueshuantong 0.45 g once a day for 2 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bailing capsule of 1.0 g three times a day for 2 months
Number of subjects: 60
Study: 18179528

Group type: EXPERIMENTAL
Intervention: Previous smoking history
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Smoking intensity-duration
Number of subjects: 88
Study: 16823067

Group type: EXPERIMENTAL
Intervention: GM-CSF (150 microg subcutaneously once daily for 14 days after the second week of radiotherapy)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No GM-CSF (control group)
Number of subjects: 29
Study: 12959731

Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stenting with predilatation
Number of subjects: 0
Study: 10624980

Group type: EXPERIMENTAL
Intervention: Tape-recorded hypnosis instructions (Group E)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 60
Study: 8923073

Group type: EXPERIMENTAL
Intervention: 20% human albumin (HA trauma, n = 14; HA sepsis, n = 14)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 10% low‐molecular‐weight HES solution (HES trauma, n = 14; HES sepsis; n = 14)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 56
Study: 1558306

Group type: EXPERIMENTAL
Intervention: Ethanol (0.85 g/kg) + Dextroamphetamine (0.09 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ethanol (0.85 g/kg) + Dextroamphetamine (0.18 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ethanol (0.85 g/kg) + Placebo Dextroamphetamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo Ethanol + Dextroamphetamine (0.09 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo Ethanol + Dextroamphetamine (0.18 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo Ethanol + Placebo Dextroamphetamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ethanol + Placebo Dextroamphetamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ethanol + Dextroamphetamine (low-dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ethanol + Dextroamphetamine (high-dose)
Number of subjects: 12
Study: 2936354

Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg, 2 times daily)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg, once daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30592344

Group type: EXPERIMENTAL
Intervention: Propofol TIVA
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sevoflurane (SEVO) inhalational anaesthesia
Number of subjects: 96
Study: 29521485

Group type: EXPERIMENTAL
Intervention: Electro-stimulation device (Veinoplus®)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Adjustable compression Velcro® wrap (Circaid Juxtafit®)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Short stretch bandage (Rosidal K®)
Number of subjects: 38
Study: 26466812

Group type: EXPERIMENTAL
Intervention: Innovative demonstration using a technique similar to 'The Newlywed Game'
Number of subjects: 100
Study: 25281044

Group type: EXPERIMENTAL
Intervention: Computer-based algorithm (CBA) with blood glucose measurement every 30 minutes
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Computer-based algorithm (CBA) with blood glucose measurement every 15 minutes
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional therapy using a fixed insulin dosing scheme
Number of subjects: 75
Study: 22721929

Group type: EXPERIMENTAL
Intervention: EDTA chelation therapy for 3 months followed by as needed for 24 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 3 months followed by weekly for 5 weeks at 6-month intervals for 24 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EDTA chelation therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 50
Study: 19966535

Group type: EXPERIMENTAL
Intervention: Training group using standard mnemonics with instructions for two transfer tasks (text learning, name-face learning, grocery list learning, place learning)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training group practicing strategies with two trained tasks without instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training group practicing strategies with two trained tasks with instructions on all transfer tasks
Number of subjects: 0
Study: 18283621

Group type: EXPERIMENTAL
Intervention: Hydrophilic guide wire (HGW)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Standard ERCP catheter
Number of subjects: 332
Study: 16340453

Group type: EXPERIMENTAL
Intervention: Alcohol (0.50 g ethanol/kg) drink
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Stress task
Number of subjects: 4

Group type: COMPARATOR
Intervention: No intervention (basal levels)
Number of subjects: 4
Study: 12461392

Group type: EXPERIMENTAL
Intervention: rhBMP-2/TSRH
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: rhBMP-2 only
Number of subjects: 25

Group type: COMPARATOR
Intervention: autograft/TSRH
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SF-36 Pain Index and PCS subscales
Number of subjects: 25
Study: 10525140

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFA) - 600 mg per day for 42 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sunflower oil (placebo) - 600 mg per day for 42 days
Number of subjects: 20
Study: 7725888

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 60
Study: 1646291

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 8 mg
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study: 7195156

Group type: EXPERIMENTAL
Intervention: 3 micrograms terbutaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 micrograms mepyramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 micrograms betamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbutaline and mepyramine
Number of subjects: 0
Study: 31452417

Group type: EXPERIMENTAL
Intervention: Midazolam plus fentanyl (0.05 mg/kg midazolam + 1.5 μg/kg fentanyl)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Midazolam plus normal saline (0.05 mg/kg midazolam + 0.03 mL/kg normal saline)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Midazolam plus fentanyl
Number of subjects: 80
Study: 27736246

Group type: EXPERIMENTAL
Intervention: 450 mg/d green tea extract (GTE)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 450 mg/d sour tea extract (STE)
Number of subjects: 54

Group type: COMPARATOR
Intervention: 450 mg/d maltodextrin (control)
Number of subjects: 54
Study: 25950231

Group type: EXPERIMENTAL
Intervention: 10% PVP-iodine rinse
Number of subjects: 38

Group type: COMPARATOR
Intervention: Water rinse (Control)
Number of subjects: 38
Study: 23982033

Group type: EXPERIMENTAL
Intervention: β-blockers or renin-angiotensin-aldosterone system blockers
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
Number of subjects: 240
Study: 21674183

Group type: EXPERIMENTAL
Intervention: Quad-helix treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 100
Study: 19953024

Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol (400/12 microg, 2 inhalations bid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17552955

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg intravenously every 3 months for four treatments
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 42
Study: 16283191

Group type: EXPERIMENTAL
Intervention: 0.2% Lavasept
Number of subjects: 67

Group type: COMPARATOR
Intervention: 1.25% PVP-iodine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 67
Study: 11901246

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10217590

Group type: EXPERIMENTAL
Intervention: Avaxim vaccine (inactivated hepatitis A vaccine), administered in two doses six months apart.
Number of subjects: 189
Study: 7775263

Group type: EXPERIMENTAL
Intervention: CPT‐11 at 80 or 90 mg/m2 plus cisplatin at 60 mg/m2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CPT‐11 at 80 or 90 mg/m2 plus cisplatin at 80 mg/m2 with granulocyte colony-stimulating factor support (2 micrograms/kg x 16 days)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: CPT‐11
Number of subjects: 23